SLXN
Silexion Therapeutics Corp Ordinary SharesSLXN
SLXN
About: Silexion Therapeutics Corp is a developmental-stage company dedicated to the development of treatments for pancreatic cancer. The company is focused on enhancing its first-generation product (LODERTM ) to develop a newly formulated product to improve the clinical efficacy against pancreatic cancer.
–
Funds holding %
of 6,740 funds
–
Analysts bullish %
Fund manager confidence
Research analyst outlook
We haven’t received any recent analyst ratings for SLXN.
Financial journalist opinion
Based on 3 articles about SLXN published over the past 30 days
Charts implemented using Lightweight Charts™